Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Invigor Medical vs Calibrate Health

Two GLP-1 desks, one scoreboard. We put Invigor Medical and Calibrate Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 9 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →
vs
No. 86 · Grade C

Calibrate Health

Visit Calibrate Health Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 74 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make Calibrate Health a bad call — it's best for readers who want year-long coaching wrap around insured branded glp-1s. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
87
32
Supply Reliability
88
87
Transparency
84
80
Access Breadth
82
86
Clinical Oversight
88
91
Track Record
90
87
Invigor MedicalBrief Score 88 · 74Calibrate Health

Price, coverage & the tracker

Invigor MedicalCalibrate Health
Brief Score88/100 (B+)74/100 (C)
Semaglutide$199/moFrom $199/mo (starting dose, 3-month plan, medication billed separately, brand-name)
Tirzepatide$339/moNot disclosed
CoverageNot disclosedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

Calibrate Health: New to the tracker on 1 August 2026. The published line reads From $199/mo (starting dose, 3-month plan, medication billed separately, brand-name) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.